Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Daniel O'Day filed a notice to sell 10,000 common shares through Morgan Stanley Smith Barney LLC on or about 01/28/2026, with an aggregate market value of $1,398,911.00 on NASDAQ.
The 10,000 shares were acquired as performance shares from the issuer on 01/31/2024. Over the past three months, O'Day has already sold 10,000 shares on each of 10/28/2025, 11/28/2025, and 12/29/2025, plus 115,640 shares on 01/23/2026, for gross proceeds ranging from about $1.19 million to $15.61 million per transaction.
Gilead Sciences Chairman and CEO Daniel P. O'Day reported an automatic option exercise and stock sale. On January 23, 2026, he exercised 115,640 non-qualified stock options at an exercise price of $66.01 per share, acquiring the same number of Gilead common shares. On the same day, he sold 115,640 common shares at a price of $135 per share. After these transactions, he directly owned 566,698 shares of Gilead common stock. The filing states that the transaction was carried out under a Rule 10b5-1 trading plan adopted on February 28, 2025, indicating it was pre-arranged under SEC rules.
Daniel O'Day has filed a notice to sell 115,640 shares of common stock, with an aggregate market value of $15,611,400.00, through Morgan Stanley Smith Barney LLC on or about 01/23/2026 on NASDAQ. The filing notes that there were 1,240,679,623 shares of this class outstanding.
The 115,640 shares to be sold were acquired on 01/23/2026 via a stock option exercise from the issuer for cash, in the same amount of 115,640 shares. Over the prior three months, O'Day sold three separate blocks of 10,000 common shares each on 10/28/2025, 11/28/2025, and 12/29/2025, with gross proceeds of $1,193,926.00, $1,265,444.00, and $1,248,272.00, respectively.
Gilead Sciences insider Deborah Telman has filed a Form 144 notice to sell up to 29,215 shares of the company’s common stock on NASDAQ. The shares, with an aggregate market value of $3,771,948.65, are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. The issuer reports 1,240,679,623 common shares outstanding.
The stock to be sold comes from a stock option exercise of 26,215 shares on 01/22/2026 paid in cash and 3,000 restricted stock units granted on 07/25/2023. The filing also lists prior Rule 10b5-1 sales for Deborah Telman over the past three months, including transactions on 11/12/2025, 12/15/2025, and 01/15/2026 with disclosed gross proceeds for each sale.
Gilead Sciences director Jeffrey Bluestone reported an option exercise and share sale. On January 20, 2026, he exercised a non-qualified stock option for 5,000 shares of Gilead common stock at an exercise price of $67.45 per share, increasing his directly held common stock to 13,920 shares and leaving 4,665 option shares outstanding. On the same day, he sold 5,000 shares of common stock at a price of $123.50 per share, resulting in a remaining direct holding of 8,920 common shares. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025, and the option vests in 25% increments every three months starting May 12, 2021.
A holder filed a notice to sell 5,000 shares of the issuer’s common stock through Morgan Stanley Smith Barney, with an aggregate market value of $617,500 on NASDAQ.
The 5,000 shares are to be sold after being acquired the same day via a stock option exercise paid in cash. The issuer has 1,240,679,623 common shares outstanding. During the prior three months, the same seller, identified as Jeffrey Bluestone of Foster City, California, sold 5,000 common shares for gross proceeds of $625,400.
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported a small, pre-planned stock sale. On January 15, 2026, he sold 3,000 shares of Gilead common stock at a price of $124.31 per share. After this transaction, he continued to beneficially own 150,503 shares of the company’s common stock in direct ownership.
The sale was executed under a Rule 10b5-1 trading plan that was adopted on August 29, 2024, meaning the trade was scheduled in advance under a preset plan rather than being decided at the time of sale.
Gilead Sciences Chief Commercial Officer Johanna Mercier reported a sale of company stock in an insider transaction. On January 15, 2026, she sold 3,000 shares of Gilead Sciences common stock at a price of $124.31 per share, reported under transaction code "S" for a sale. After this transaction, she beneficially owned 103,221 shares of Gilead common stock in direct ownership.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan, which was adopted on February 20, 2025. Such plans allow insiders to pre-arrange trades according to preset instructions, providing a structured way to sell shares over time.
Johanna Mercier has filed a Form 144 notice to sell 3,000 shares of common stock through Morgan Stanley Smith Barney on or about 01/15/2026 on the NASDAQ market. The planned sale has an aggregate market value of $372,930.00, and the issuer has 1,240,679,623 shares outstanding. The shares to be sold come from restricted stock and performance share awards acquired from the issuer in early 2024.
Over the past three months, Johanna Mercier has already sold 3,000 and 28,000 shares of common stock in separate transactions, with gross proceeds of $366,000.00 and $3,524,173.10, respectively. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
An insider has filed a Rule 144 notice to sell 3,000 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $372,930.00. The filing notes that there were 1,240,679,623 shares outstanding of this class, providing context for the size of the planned sale.
The shares to be sold were acquired on 01/24/2023 as performance shares from the issuer, with 3,000 securities acquired and deemed fully paid as of that date. The notice indicates an approximate sale date of 01/15/2026 on the NASDAQ exchange.
In the past three months, the person for whose account the securities are to be sold, Andrew Dickinson, has already sold 3,000 common shares on 12/15/2025 for gross proceeds of $366,000.00 and 2,500 common shares on 11/17/2025 for gross proceeds of $313,075.00. By signing, the seller represents that they do not know of undisclosed material adverse information about the issuer’s operations.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
